Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BA 7602-06; LOMUCIN; MSI 1995

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bago
  • Class Antiasthmatics; Antirheumatics; Benzofurans; Nonsteroidal anti-inflammatories; Pyridines; Small molecules
  • Mechanism of Action Mucin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cystic fibrosis; Gastrointestinal disorders

Most Recent Events

  • 28 May 2008 Talniflumate is available for licensing (http://www.genaera.com/business_development.php)
  • 05 Jul 2007 Discontinued - Phase-II for Cystic fibrosis in Ireland (PO)
  • 19 Apr 2005 No development reported - Phase-I for Asthma in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top